Filing Details
- Accession Number:
- 0001415889-24-002613
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-02-05 17:39:10
- Reporting Period:
- 2024-02-01
- Accepted Time:
- 2024-02-05 17:39:10
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1649094 | Vaxcyte Inc. | PCVX | Biological Products, (No Disgnostic Substances) (2836) | 464233385 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1918033 | Mikhail Eydelman | C/O Vaxcyte, Inc. 825 Industrial Road, Suite 300 San Carlos CA 94070 | Svp, Gen Counsel & Corp Sec | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2024-02-01 | 1,667 | $21.41 | 22,377 | No | 4 | M | Direct | |
Common Stock | Disposition | 2024-02-01 | 212 | $72.22 | 22,165 | No | 4 | S | Direct | |
Common Stock | Disposition | 2024-02-01 | 638 | $73.17 | 21,527 | No | 4 | S | Direct | |
Common Stock | Disposition | 2024-02-01 | 343 | $74.11 | 21,184 | No | 4 | S | Direct | |
Common Stock | Disposition | 2024-02-01 | 474 | $75.39 | 20,710 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2024-02-01 | 1,667 | $0.00 | 1,667 | $21.41 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
191,666 | 2032-05-08 | No | 4 | M | Direct |
Footnotes
- The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 29, 2023.
- The price reported is a weighted-average price. The shares were sold at prices ranging from $71.69 to $72.50. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- The price reported is a weighted-average price. The shares were sold at prices ranging from $72.695 to $73.67. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- The price reported is a weighted-average price. The shares were sold at prices ranging from $73.70 to $74.52. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- The price reported is a weighted-average price. The shares were sold at prices ranging from $75.01 to $75.70. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- 1/4 of the shares subject to the option shall vest on April 1, 2023, and 1/48 of the shares shall vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date.